• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-05-28

  This study demonstrates that activation of PPARγ directs macrophage polarization from a proinflammatory M1 state toward an anti-inflammatory M2 phenotype, ameliorating symptoms in a dextran sulfate sodium-induced mouse model of inflammatory bowel disease. Findings clarify the mechanistic role of the STAT-1/STAT-6 pathway, providing a foundation for immunometabolic research targeting macrophage-driven inflammation.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Use and Q

  2026-05-28

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables specific, sensitive detection of goat IgG in immunofluorescence-based workflows such as ICC, IHC, flow cytometry, and ELISA. It should only be used with goat primary antibodies and is not appropriate for detection of other species’ primaries or for applications outside validated immunodetection workflows. Proper storage, handling, and protocol adherence are essential to maximize signal and minimize background.

• Doxorubicin for Cancer Research: Protocols, Workflows & Tips

  2026-05-27

  Doxorubicin (Adriamycin) is a gold-standard chemotherapeutic agent for modeling DNA damage, apoptosis, and synergistic drug responses in solid tumor and hematologic malignancy research. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights to help you maximize experimental rigor and translational relevance.

• SCH772984: Potent ERK1/2 Inhibitor for Oncogenic MAPK Resear

  2026-05-27

  SCH772984 is a selective ATP-competitive ERK1/2 inhibitor with nanomolar potency, enabling precise MAPK/ERK pathway inhibition in BRAF, NRAS, and KRAS mutant tumor models. Its high selectivity and robust in vivo efficacy, particularly in combination therapy, make it a cornerstone reagent for translational cancer research.

• QPRT Drives Breast Cancer Invasion via PLC-Dependent MLC Pho

  2026-05-26

  This study establishes quinolinate phosphoribosyltransferase (QPRT) as a driver of breast cancer invasiveness, operating through enhanced myosin light chain phosphorylation and the PLC signaling pathway. The findings offer mechanistic insight into cancer cell migration and suggest new therapeutic angles targeting purinergic signaling and PLC activity.

• SMYD2 Inhibition Overcomes Drug Resistance in Renal Cell Car

  2026-05-26

  This study uncovers how SMYD2, a histone methyltransferase, drives tumor progression and multi-drug resistance in clear cell renal cell carcinoma (ccRCC). By linking SMYD2 activity to miR-125b regulation and P-glycoprotein-mediated drug efflux, the paper provides mechanistic insight and preclinical evidence for targeting epigenetic regulators to enhance chemotherapeutic efficacy.

• KPT330 Enhances CRISPR-Cas9 Specificity via mRNA Export Cont

  2026-05-25

  The reference study demonstrates that KPT330, a selective inhibitor of nuclear export (SINE), improves the precision of CRISPR-Cas9 genome and base editing by modulating the nuclear export of Cas9 mRNA. This finding introduces a novel, indirect strategy to limit off-target effects in genome engineering, with implications for improving CRISPR-based editing workflows.

• Cy3-dCTP: Precision Fluorescent DNA Labeling for Translation

  2026-05-25

  Explore how Cyanine 3-dCTP (Cy3-dCTP) advances direct enzymatic DNA and cDNA labeling, bridging mechanistic insight with practical guidance for translational researchers. This article contextualizes APExBIO’s Cy3-dCTP within modern breakthroughs in enzymatic oligonucleotide synthesis, highlights strategic considerations for competitive workflow design, and outlines future directions informed by recent advances in DNA nanoframeworks.

• Praeruptorin A: Angular Pyranocoumarin Innovation in Cell Mo

  2026-05-24

  Praeruptorin A, a next-generation angular pyranocoumarin compound, empowers researchers with multi-pathway control for modeling inflammation, ferroptosis, and metastasis. This guide details protocol enhancements, workflow integration, and troubleshooting strategies, leveraging new insights from recent mechanistic studies to maximize impact in preclinical research.

• EDI3 Inhibition Reduces Tumor Growth in HER2+ Resistant Brea

  2026-05-23

  Keller et al. demonstrate that targeting the glycerophosphodiesterase EDI3 impairs viability and tumor growth in ER-HER2+ breast cancer cells resistant to standard HER2-directed therapies. Their findings highlight EDI3 as a promising metabolic vulnerability and suggest new research directions for overcoming therapeutic resistance.

• Palomid 529 (P529): Optimizing PI3K/Akt/mTOR Pathway Inhibit

  2026-05-22

  Palomid 529 (P529) delivers robust, dual mTORC1/mTORC2 inhibition for translational cancer research, especially in models of metastasis and drug resistance. This guide details workflow enhancements, troubleshooting, and data-driven insights that empower precise experimental design when targeting the PI3K/Akt/mTOR pathway.

• Annexin V-PE Reagent: Redefining Early Apoptosis Detection i

  2026-05-22

  This thought-leadership article explores how the Annexin V-PE Reagent, a leading Annexin V fluorescent conjugate from APExBIO, is transforming the precision and strategic deployment of cell death assays in translational immunotherapy. By integrating mechanistic insights from cutting-edge CD38 CAR-T structural studies, it provides actionable guidance for researchers striving to optimize apoptosis detection, enhance CAR-T preclinical workflows, and drive safer, more effective clinical translation. The discussion bridges the gap between structural biology and assay innovation, outlining new best practices and future horizons for apoptosis analysis in next-generation cell therapies.

• Redefining Apoptosis Detection in ccRCC: Translational Strat

  2026-05-21

  Explore how advanced apoptosis detection tools, such as the Annexin V-APC/7-AAD Apoptosis Kit, are revolutionizing mechanistic and translational research in clear cell renal cell carcinoma (ccRCC). This article bridges new glyco-immune checkpoint insights with experimental best practices, offering actionable strategic guidance for translational scientists.

• Triamcinolone Protocols: Synthetic Glucocorticoid Agonist Gu

  2026-05-21

  Triamcinolone is a synthetic glucocorticoid agonist designed for investigating glucocorticoid signaling, anti-inflammatory mechanisms, and immunosuppression in vitro. This product provides high-purity material for research workflows requiring precise modulation of receptor-driven pathways, but is not suitable for diagnostic or clinical applications.

• Pharmacokinetics of Vernakalant Hydrochloride: CYP2D6 and AF

  2026-05-20

  This study provides the first comprehensive clinical pharmacokinetic analysis of Vernakalant Hydrochloride (RSD1235), focusing on the impact of CYP2D6 metabolism and other patient factors in rapid atrial fibrillation conversion. The findings support Vernakalant's dose-proportional kinetics and show that CYP2D6 phenotype does not significantly alter exposure during intravenous administration, streamlining its use in acute AF treatment.

16381 records 1/1093 page Next 12345 下5页 Last page